Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, 30130-100, Minas Gerais, Brazil.
Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, 88806-000, Santa Catarina, Brazil.
Microb Pathog. 2022 Jan;162:105341. doi: 10.1016/j.micpath.2021.105341. Epub 2021 Dec 6.
Serological tests used for the diagnosis of tegumentary leishmaniasis (TL) presents problems, mainly related to their variable sensitivity and/or specificity, which can be caused by low levels of antileishmanial antibodies or by presence of cross-reactive diseases, respectively. In this context, the search for new antigenic candidates presenting higher sensitivity and specificity is urgently required. In the present study, the amino acid sequences of the LiHyT, LiHyD, LiHyV, and LiHyP proteins, which were previously showed to be antigenic in the visceral leishmaniasis (VL), were evaluated and eight B-cell epitopes were predicted and used for construction of gene codifying a chimeric protein called ChimLeish. The protein was expressed, purified and evaluated as a recombinant antigen in ELISA (Enzyme-Linked Immunosorbent Assay) for the diagnosis of TL. The own B cell epitopes used to construct the chimera were synthetized and also evaluated as antigens, as well as a soluble Leishmania braziliensis antigenic extract (SLA). Results showed that ChimLeish presented 100% sensitivity and specificity to diagnose TL, while synthetic peptides showed sensitivity varying from 9.1% to 90.9%, while specificity reached from 98.3% to 99.1%. SLA showed sensitivity and specificity of 18.2% and 98.3%, respectively. A preliminary prognostic evaluation showed that anti-ChimLeish IgG antibodies declined in significant levels, when serological reactivity was compared before and six months after treatment, suggesting also a possible prognostic role of this antigen for TL.
用于诊断皮肤利什曼病(TL)的血清学检测存在问题,主要与它们的可变敏感性和/或特异性有关,这可能是由抗利什曼原虫抗体水平低或存在交叉反应性疾病引起的。在这种情况下,迫切需要寻找具有更高敏感性和特异性的新抗原候选物。在本研究中,评估了 LiHyT、LiHyD、LiHyV 和 LiHyP 蛋白的氨基酸序列,这些蛋白先前在内脏利什曼病(VL)中显示出抗原性,预测了 8 个 B 细胞表位,并用于构建编码一种称为 ChimLeish 的嵌合蛋白的基因。该蛋白在 ELISA(酶联免疫吸附试验)中作为重组抗原进行表达、纯化和评估,用于诊断 TL。用于构建嵌合体的自身 B 细胞表位被合成并作为抗原进行评估,以及一种可溶性巴西利什曼原虫抗原提取物(SLA)。结果表明,ChimLeish 对诊断 TL 具有 100%的敏感性和特异性,而合成肽的敏感性从 9.1%到 90.9%不等,特异性从 98.3%到 99.1%不等。SLA 的敏感性和特异性分别为 18.2%和 98.3%。初步预后评估表明,当比较治疗前后六个月的血清学反应时,抗 ChimLeish IgG 抗体水平显著下降,这也表明该抗原可能对 TL 具有预后作用。